It was found that the tumor specificity of MSN was improved with the addition of chitosan (targeting acid PH) and urokinase plasminogen activator (UPA, targeting UPAR), ensuring drug release and accumulation preferentially at the pancreatic tumors compared to liver or kidney. This evidence concerns the gene PLAUR and pancreatic neoplasm.